Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.

Clin Med Insights Oncol · 2022 · PMC8891891 · PMID 35250326

Europe PMC DOI

hedged sentence

0.1670

closest p · 3.3× alpha

0.1670

boldest claim

The sentences

did not reach statistical significanceP = .167not close (p > 0.1)

Patients with brain metastases seemed to have worse OS than those without brain metastases according to the Kaplan-Meier survival curve although their differences did not reach statistical significance ( P = .167; Figure 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.